Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chiesi Global Rare Diseases and Protalix BioTherapeutics have received approval from the US Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) to treat Fabry disease in adult patients.
PRX-102 is indicated to treat Fabry disease in adult patients. Credit: ProteinBoxBot at English Wikipedia/ commons.wikimedia.org.
Subscribe to our email newsletter
The latest move follows the receipt of marketing authorisation for PRX-102 from the European Commission (EC) for the same indication.
The PEGylated enzyme replacement therapy (ERT), PRX-102 is a recombinant human α‑Galactosidase‑A enzyme expressed in plant-cell culture that is designed for providing a long half-life.
The therapy was found to have an initial half-life of 78.9 ± 10.3 hours, in clinical trials.
Chiesi Global Rare Diseases head Giacomo Chiesi said: “While much progress has been made in the treatment of Fabry disease, there is still a need for new treatment options.
“We established Chiesi Global Rare Diseases to deliver innovative therapies and solutions for people affected by rare diseases.
“With the FDA approval of PRX-102, we can now offer people living with Fabry disease an alternative treatment option.”
PRX-102’s tolerability, efficacy, and safety has been evaluated in a comprehensive clinical development programme, which was conducted in over 140 patients, who have received follow up treatment for up to 7.5 years.
It has been investigated in ERT-experienced and ERT-naïve patients, including in a head-to-head trial.
The therapy showed non-inferior efficacy to agalsidase beta in controlling the estimated glomerular filtration rate (eGFR) decline.
Protalix BioTherapeutics president and CEO Dror Bashan said: “We are extremely pleased to receive FDA approval of PRX-102 for the treatment of adult patients with Fabry disease.
“This approval is a testament to the dedication of the Protalix and Chiesi teams to deliver this much needed new therapeutic option to patients in need.
“The totality of clinical data suggests that PRX-102 has the potential to be a long-lasting therapy.”
